Mohammad Kamran, MD
Rheumatology · Marietta, GANPI 1811194681
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Aurinia Pharma U.S., Inc. accounts for 61.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $11,800 and has fallen 52.9% since, to $5,558 in 2025. Among rheumatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $94.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$20K
- Sobi, Inc$4K
- GSK$2K
- AbbVie$2K
- Amgen$1K
- Novartis$604
- plus $2K from 18 others
Across 1 payment — averaging $7500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aurinia Pharma U.S., Inc.$8K
What the payments were for
- Consulting fees$5,94818%
- Speaking & faculty fees$18,39056%
- Travel & lodging$7432%
- Food & beverage$7,50523%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 27 | $20,087 |
| Sobi, Inc | 4 | $4,256 |
| GSK | 15 | $2,092 |
| AbbVie | 96 | $1,977 |
| Amgen(2 entities) | 57 | $1,196 |
| Novartis | 30 | $604 |
| UCB, Inc. | 16 | $486 |
| E.r. Squibb & Sons, L.L.C. | 26 | $447 |
| AstraZeneca(2 entities) | 14 | $307 |
| Johnson & Johnson | 10 | $213 |
| Boehringer Ingelheim | 10 | $183 |
| Pfizer | 8 | $123 |
| Sanofi | 4 | $105 |
| Mallinckrodt Hospital Products Inc. | 4 | $83 |
| Ferring Pharmaceuticals Inc. | 4 | $81 |
| Octapharma USA, Inc. | 4 | $75 |
| Radius Health, Inc. | 3 | $75 |
| Lilly USA, LLC | 4 | $66 |
| Genentech USA, Inc. | 3 | $60 |
| Medexus Pharma, Inc. | 4 | $52 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Sandoz | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,652 in reported general payments places this provider in the 90th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 128 | $913,244 |
| Enbrel SureclickEtanercept | 107 | $791,142 |
| OtezlaApremilast | 38 | $213,253 |
| XeljanzTofacitinib Citrate | 17 | $93,454 |
| ForteoTeriparatide | 22 | $90,703 |
| Enbrel MiniEtanercept | 13 | $89,353 |
| Actemra ActpenTocilizumab | 17 | $80,374 |
| Taltz AutoinjectorIxekizumab | 12 | $79,078 |
| Orencia ClickjectAbatacept | 12 | $63,867 |
| Teriparatide | 18 | $26,517 |
| ProliaDenosumab | 14 | $23,951 |
| Hydroxychloroquine Sulfate | 663 | $23,558 |
| Leflunomide | 185 | $9,851 |
| Duloxetine Hcl | 413 | $8,864 |
| MethotrexateMethotrexate Sodium | 358 | $8,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Prolia | $1,196 | $237,20452 claims |
| PfizerXeljanz | $123 | $93,45417 claims |
| Lilly USA, LLCForteo | $66 | $90,70322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Marietta
- Mohammed AbubakerMarietta$218K
- Roel QuerubinMarietta$24K
- Ritesh KohliMarietta$18K
- Xena WhittierMarietta$13K
- Javeria BhawalMarietta$12K
- James MossellTifton$1.6M
- Gary MyersonAtlanta$1M
- Theresa Lawrence FordLawrenceville$410K
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.